MX367301B - Liberacion de agentes biologicamente activos utilizando disolventes hidrofobicos volatiles. - Google Patents

Liberacion de agentes biologicamente activos utilizando disolventes hidrofobicos volatiles.

Info

Publication number
MX367301B
MX367301B MX2015005677A MX2015005677A MX367301B MX 367301 B MX367301 B MX 367301B MX 2015005677 A MX2015005677 A MX 2015005677A MX 2015005677 A MX2015005677 A MX 2015005677A MX 367301 B MX367301 B MX 367301B
Authority
MX
Mexico
Prior art keywords
volatile
biologically
delivery
active agents
hydrophobic
Prior art date
Application number
MX2015005677A
Other languages
English (en)
Other versions
MX2015005677A (es
Inventor
Beal Salamone Ann
Charles Salamone Joseph
Chen Xiaoyu
Elizabeth Reilly Katelyn
Original Assignee
Rochal Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rochal Ind Llc filed Critical Rochal Ind Llc
Publication of MX2015005677A publication Critical patent/MX2015005677A/es
Publication of MX367301B publication Critical patent/MX367301B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una composición y un método adaptados para la administración de agentes biológicamente activos hidrofílicos. La composición puede incluir una microemulsión revertida formada por al menos un agente biológicamente activo hidrofílico solubilizado mediante un surfactante de emulsión revertida en un disolvente hidrofóbico volátil no pungente. El disolvente hidrofóbico volátil no pungente es seleccionado a partir del grupo que comprende siloxanos volátiles lineales y cíclicos, alcanos volátiles lineales, ramificados y cíclicos, fluorocarbonos y clorofluorocarbonos volátiles, dióxido de carbono líquido bajo presión, y combinaciones de los mismos. La microemulsión revertida puede ser una solución ópticamente clara.
MX2015005677A 2012-11-06 2013-10-21 Liberacion de agentes biologicamente activos utilizando disolventes hidrofobicos volatiles. MX367301B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723113P 2012-11-06 2012-11-06
PCT/US2013/065928 WO2014074289A1 (en) 2012-11-06 2013-10-21 Delivery of biologically-active agents using volatile, hydrophobic solvents

Publications (2)

Publication Number Publication Date
MX2015005677A MX2015005677A (es) 2016-02-05
MX367301B true MX367301B (es) 2019-08-14

Family

ID=50622591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005677A MX367301B (es) 2012-11-06 2013-10-21 Liberacion de agentes biologicamente activos utilizando disolventes hidrofobicos volatiles.

Country Status (11)

Country Link
US (1) US8852648B2 (es)
EP (1) EP2916820B1 (es)
JP (1) JP6267218B2 (es)
AU (1) AU2013341646B2 (es)
BR (1) BR112015010253A2 (es)
CA (1) CA2890333C (es)
ES (1) ES2962574T3 (es)
HK (1) HK1212231A1 (es)
MX (1) MX367301B (es)
NZ (1) NZ707855A (es)
WO (1) WO2014074289A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048249A1 (en) 2005-08-24 2007-03-01 Purdue Research Foundation Hydrophilized bactericidal polymers
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
EP2745851B1 (en) 2012-12-21 2017-04-12 Mölnlycke Health Care AB Method for attachment of medical devices to surfaces
US11180690B2 (en) * 2013-03-14 2021-11-23 Flotek Chemistry, Llc Diluted microemulsions with low surface tensions
US9868893B2 (en) * 2013-03-14 2018-01-16 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9446079B2 (en) 2013-07-11 2016-09-20 Links Medical Products, Incorporated Honey and silver nitrate composition, composition dressing and methods of making same
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN103948691B (zh) * 2014-05-14 2016-08-31 广西大学 一种含有赤芍和磺胺间甲氧嘧啶钠的畜禽用复方药物
CA2956596A1 (en) * 2014-07-31 2016-02-04 Noven Pharmaceuticals, Inc. Silicone-containing acrylic polymers for transdermal drug delivery compositions
US20160095876A1 (en) 2014-10-01 2016-04-07 Rochal Industries, Llp Composition and kits for inhibition of pathogenic microbial infection and methods of using the same
US9364402B1 (en) * 2014-12-31 2016-06-14 The Dial Corporation Analgesic cleansing composition
US10716305B2 (en) 2015-01-23 2020-07-21 Biocidium Biopharmaceuticals Inc. Anti-bacterial compositions
EP3280769B1 (en) 2015-04-06 2022-03-16 3M Innovative Properties Company Removable film forming gel compositions and methods for their application
WO2017019503A1 (en) * 2015-07-24 2017-02-02 Teleflex Medical Incorporated Wound care products comprising alexidine
CN109562182A (zh) 2016-06-02 2019-04-02 先进科学发展公司 包含桉树脑和阿莫西林的药物制剂
BR112018076184A2 (pt) * 2016-06-16 2019-03-26 The University Of Liverpool composição sólida, composição farmacêutica ou veterinária na forma injetável, formulação intramuscularmente injetável, formulação subcutaneamente injetável, dispersão aquosa, dispersão oleosa, processos para preparar uma composição sólida, uma dispersão aquosa e uma dispersão oleosa, métodos para tratar e/ou prevenir uma infecção parasítica ou fúngica e para prevenir malária, e, kit para preparação de uma formulação líquida estéril de nanopartículas de atovaquona para injeção.
US10076552B2 (en) 2016-08-09 2018-09-18 DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof
ES2785322T3 (es) 2016-10-11 2020-10-06 Ionia Azure Ag Microemulsión de agua en aceite cosmética
JP2020508992A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド ざ瘡の処置のためのカンナビノイドの製剤
CA3053500A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
CN110392528A (zh) * 2017-03-01 2019-10-29 埃科莱布美国股份有限公司 通过高分子量聚合物减少吸入危险的消毒剂和杀菌剂
WO2018218177A2 (en) * 2017-05-26 2018-11-29 Florida Chemical Company, Inc. Microemulsions for agricultural use
US20180340046A1 (en) 2017-05-27 2018-11-29 Poly Group LLC Dispersible antimicrobial complex and coatings therefrom
WO2018222902A1 (en) 2017-06-02 2018-12-06 Extreme Fire Solutions, Llc Fire extinguishing systems and compositions and methods of use thereof
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2018232417A1 (en) 2017-06-16 2018-12-20 Poly Group LLC Polymeric antimicrobial surfactant
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
EP3727338A1 (en) * 2017-12-19 2020-10-28 University of Tennessee Research Foundation W/o/w microemulsions for ocular administration
CN108477293B (zh) * 2018-03-30 2021-11-05 山东省农药检定所 一种蒜薹保鲜烟剂
EP3578181A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies
WO2021033145A1 (en) * 2019-08-19 2021-02-25 Leiutis Pharmaceuticals Pvt Ltd Novel injectable formulations of artesunate
WO2021209025A1 (en) * 2020-04-17 2021-10-21 Shenzhen Pharmacin Co., Ltd Pharmaceutical compositions
US20230172880A1 (en) * 2020-05-01 2023-06-08 Achelon, Inc. Fast-acting topical anesthetic formulations
CN112094279B (zh) * 2020-09-25 2022-11-18 西南大学 对氨基水杨酸双氢青蒿素类衍生物及其制备方法和应用
CN113004301B (zh) * 2021-03-11 2022-02-18 广西师范大学 一种青蒿琥酯基-二苯基脲衍生物ars-dpu及其制备方法与应用
CN115737611B (zh) * 2022-12-01 2024-05-14 成都科宏达科技有限公司 一种低温稳定的动物药浴液

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719235A (en) 1984-10-16 1988-01-12 Gerald N. Kern Methods and compositions for treating viral infection
US4885310A (en) 1985-05-09 1989-12-05 Gerald N. Kern Anti-fungal methods and agent
US4717737A (en) 1985-06-05 1988-01-05 Gerald N. Kern Anti-bacterial methods and agent
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
US5103812A (en) 1988-10-12 1992-04-14 Rochal Industries, Inc. Conformable bandage and coating material
EP0684832A4 (en) 1993-02-17 1996-09-11 Smithkline Beecham Corp MICROEMULSIONS CONTAINING PHARMACEUTICAL COMPOSITIONS.
JPH072689A (ja) * 1993-04-19 1995-01-06 Advanced Sukin Res Kenkyusho:Kk 難吸収性物質を含有するマイクロエマルション製剤
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
CA2366601C (en) 1999-03-25 2010-06-01 3M Innovative Properties Company Non-stinging coating composition
EP1369113B1 (en) * 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Solubilisation of drugs in HFA propellant by means of emulsions
US20050269204A1 (en) * 2004-06-04 2005-12-08 Applera Corporation Reverse emulsion with biological material
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
ATE499955T1 (de) * 2005-12-07 2011-03-15 Rochal Ind Llp Anpassbarer verband und überzugsmaterial
CN102665734A (zh) * 2009-09-25 2012-09-12 法马索尔有限公司 皮肤用表面涂层
US20120115812A1 (en) * 2009-09-25 2012-05-10 Pharmasol Corporation Surface coatings for skin
DE102010006612A1 (de) * 2010-02-01 2011-08-04 Beiersdorf AG, 20253 Stabilisierte Zubereitungen auf Basis einer Wasser in Silikon - oder Silikon in Wasser-Emulsion umfassend Butylenglykole
US9346982B2 (en) 2010-08-16 2016-05-24 Convatec Technologies Inc. Amphiphilic pressure sensitive adhesives for human skin adhesion
WO2012071251A1 (en) 2010-11-24 2012-05-31 Pharmasol Corporation Aerosol emulsions
US8263720B1 (en) 2011-10-05 2012-09-11 Rochal Industries, Llp Sacrificial adhesive coatings

Also Published As

Publication number Publication date
EP2916820A1 (en) 2015-09-16
JP6267218B2 (ja) 2018-01-24
MX2015005677A (es) 2016-02-05
EP2916820A4 (en) 2016-06-08
AU2013341646B2 (en) 2017-08-31
ES2962574T3 (es) 2024-03-19
WO2014074289A1 (en) 2014-05-15
CA2890333C (en) 2021-03-23
HK1212231A1 (en) 2016-06-10
NZ707855A (en) 2018-11-30
US20140127320A1 (en) 2014-05-08
EP2916820B1 (en) 2023-10-11
CA2890333A1 (en) 2014-05-15
US8852648B2 (en) 2014-10-07
BR112015010253A2 (pt) 2017-07-11
JP2015535281A (ja) 2015-12-10
AU2013341646A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
MX2015005677A (es) Liberacion de agentes biologicamente activos utilizando disolventes hidrofobicos volatiles.
EP3650060A3 (en) Ambulatory infusion pumps and reservoir assemblies for use with same
MX2022013322A (es) Portadores lipidos nanoestructurados y emulsiones estables y usos de los mismos.
WO2015106269A8 (en) Rapid action insulin formulations and pharmaceutical delivery systems
CL2015001852A1 (es) Películas de ésteres de poli alfa-1, 3-glucano y metodo para su preparación
AU2014318696B2 (en) Liquid protein formulations containing organophosphates
SG10201808743VA (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
PH12015500115A1 (en) Glucagon analogues
EP4218411A3 (en) Stabilization and isolation of extracellular nucleic acids
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
MX360638B (es) Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
WO2015095624A3 (en) Drug mixing and delivery system and method
CZ308492B6 (cs) Kosmetická kompozice na bázi kyseliny hyaluronové, způsob její přípravy a použití
MX2018003705A (es) Metodos para producir formulaciones de glucagon terapeuticas estables en solventes polares aproticos.
NZ630763A (en) Apixaban liquid formulations
BR112018072017A2 (pt) composição de limpeza ácida pulverizável com nebulização reduzida, sistema para aplicar a composição de limpeza, e, método para limpar uma superfície dura.
WO2014043556A3 (en) Polytetrafluoroethylene co-polymer emulsions
WO2013167736A3 (en) Foam control formulations
EP3274548A4 (en) METHODS AND COMPOSITIONS FOR INJECTING ACTIVE SOLUTIONS OF HIGH CONCENTRATION AND / OR HIGH VISCOSITY
BR112017002356A2 (pt) composições de formulação líquida, dispositivos de entrega de medicamento e métodos para preparação e uso dos mesmos
AR100618A1 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
CL2012001835A1 (es) Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.
EA201492084A1 (ru) Фтористые добавки для применения во фторсодержащей обрабатывающей жидкости
WO2015164387A3 (en) Systems, methods, and apparatus for providing machine-to-machine and consumer-to-machine interaction application platforms

Legal Events

Date Code Title Description
FG Grant or registration